
Oncology NEWS International
- Oncology NEWS International Vol 18 No 3
- Volume 18
- Issue 3
Champions strikes deal with Concordia
Champions Biotechnology has obtained royalty rights to Concordia Pharmaceuticals’ Salirasib (farsnesyl thiosalicylic acid), an RAS antagonist.
Champions Biotechnology has obtained royalty rights to Concordia Pharmaceuticals’ Salirasib (farsnesyl thiosalicylic acid), an RAS antagonist.
As a part of the royalty agreement, Champions will use its Biomerk Tumorgraft Preclinical Platform to evaluate a combination therapy indication for the compound.
Articles in this issue
almost 17 years ago
Genetics opens new window on acute myeloid leukemiaalmost 17 years ago
Pralatrexate: Upfront Rx strategy for T-cell lymphomaalmost 17 years ago
Who's Newsalmost 17 years ago
Functional MRI boosts early staging of cervical canceralmost 17 years ago
Unseen bone lesions flare up on post-Rx NSCLC scansalmost 17 years ago
Exercise jumpstarts quality of life in lung caalmost 17 years ago
Oncolytics kicks off reovirus trialalmost 17 years ago
PET/CT picks up additional lesions not found on chest CTalmost 17 years ago
Targeted therapies address hard-to-treat liver tumorsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.



































